Accedi

The pharmacokinetic journey of drugs from solid oral dosage forms into systemic circulation is multifaceted. It begins with disintegration, a prerequisite ensuring a solid dosage form's subdivision into minute particles. Dissolution occurs next as these granulated entities solubilize in gastrointestinal fluids. This solubilization is crucial for the succeeding stage, permeation, which describes the traversal of the drug across the intestinal membrane and its subsequent entry into the blood circulation.

Critically, drug absorption kinetics can be impeded by either the rate of dissolution or permeation. The dissolution rate is a limiting factor, particularly for lipophilic substances and drugs with inherently low aqueous solubility, including extended-release formulations. Permeation, on the other hand, governs the absorption rate in hydrophilic drugs, dictating their transport through lipid bilayers.

The Biopharmaceutics Classification System (BCS) stratifies drugs into four classes based on their solubility and permeability attributes. Class I compounds exhibit high solubility and permeability and are readily absorbed. Class II drugs are hindered by poor solubility, Class III by diminished permeability, and Class IV face absorption challenges attributed to both low solubility and permeability. Examples include diltiazem (Class I), nifedipine (Class II), insulin (Class III), and taxol (Class IV).

A critical pharmacokinetic parameter, dissolution rate, is also quantified as the rate at which a drug transitions from a solid state to a solubilized form within a given solvent under controlled conditions. Solubility challenges substantially impact the dissolution rate, notably for compounds with aqueous solubility below 1-2 mg/ml within the gastrointestinal pH range of 2 to 8. Nevertheless, drugs such as cisapride overcome low intrinsic solubility through a swift dissolution rate and small therapeutic dose, ensuring sufficient absorption within the gastrointestinal transit period. Dissolution dynamics correlate more with overall drug absorption and bioavailability than absolute solubility.

Dal capitolo 3:

article

Now Playing

3.19 : Factors Influencing Drug Absorption: Drug Dissolution

Pharmacokinetics: Drug Absorption

357 Visualizzazioni

article

3.1 : Drug Administration and Therapy Phases: Overview

Pharmacokinetics: Drug Absorption

355 Visualizzazioni

article

3.2 : Drug Absorption: Overview

Pharmacokinetics: Drug Absorption

419 Visualizzazioni

article

3.3 : Drug Delivery: Overview

Pharmacokinetics: Drug Absorption

225 Visualizzazioni

article

3.4 : Drug Delivery: Enteral Route

Pharmacokinetics: Drug Absorption

302 Visualizzazioni

article

3.5 : Drug Delivery: Parenteral Route

Pharmacokinetics: Drug Absorption

299 Visualizzazioni

article

3.6 : Drug Delivery: Miscellaneous Routes

Pharmacokinetics: Drug Absorption

258 Visualizzazioni

article

3.7 : Cellular Membranes and Drug Transport

Pharmacokinetics: Drug Absorption

211 Visualizzazioni

article

3.8 : Mechanisms of Drug Absorption: Paracellular, Transcellular, and Vesicular Transport

Pharmacokinetics: Drug Absorption

271 Visualizzazioni

article

3.9 : Passive Diffusion: Overview and Kinetics

Pharmacokinetics: Drug Absorption

263 Visualizzazioni

article

3.10 : Pore Transport and Ion-Pair Transport

Pharmacokinetics: Drug Absorption

273 Visualizzazioni

article

3.11 : Carrier-Mediated Transport

Pharmacokinetics: Drug Absorption

198 Visualizzazioni

article

3.12 : Facilitated Diffusion

Pharmacokinetics: Drug Absorption

234 Visualizzazioni

article

3.13 : Active Transport

Pharmacokinetics: Drug Absorption

319 Visualizzazioni

article

3.14 : Vesicular Trasport: Endocytosis, Transcytosis and Exocytosis

Pharmacokinetics: Drug Absorption

488 Visualizzazioni

See More

JoVE Logo

Riservatezza

Condizioni di utilizzo

Politiche

Ricerca

Didattica

CHI SIAMO

Copyright © 2025 MyJoVE Corporation. Tutti i diritti riservati